Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Nick Mulcahy

    News

    Soon-to-be medical student awarded $10K after spotting melanoma

    Author:
    Nick Mulcahy
    Publish date: January 6, 2022

    “The mole on the back of your neck is possibly cancerous. Please go see a doctor!”

    • Read More

    News

    FDA approves time-saving combo for r/r multiple myeloma

    Author:
    Nick Mulcahy
    Publish date: December 2, 2021

    “The approval will help clinicians address unmet patient needs by reducing the administration time from hours to just minutes and reducing the...

    • Read More

    News

    What’s hot at the world’s premiere breast cancer meeting

    Author:
    Nick Mulcahy
    Publish date: December 1, 2021

    An important study of an investigational oral agent for postmenopausal women who have been treated for ER positive advanced breast cancer...

    • Read More

    News

    After doc uproar, NCCN reverses prostate cancer guidance

    Author:
    Nick Mulcahy
    Publish date: December 1, 2021

    This advice aligns closely with the group’s initial recommendation, published over a decade ago.

    • Read More

    News

    FDA approves imaging drug for detecting ovarian cancer lesions

    Author:
    Nick Mulcahy
    Publish date: November 30, 2021

    Drug inventor Philip Low, PhD, said the agent causes ovarian cancer lesions to “light up like stars against a night sky.”

    • Read More

    News

    EU panel endorses first-of-its-kind lung cancer drug

    Author:
    Nick Mulcahy
    Publish date: November 16, 2021

    Sotorasib is an inhibitor of KRAS G12C, an oncogenic driver of tumorigenesis.

    • Read More

    News

    Shock, disbelief as NCCN changes prostate cancer guidance

    Author:
    Nick Mulcahy
    Publish date: November 15, 2021

    “To suggest for a millisecond that active surveillance isn’t the preferred method for low-risk men is bizarre thinking ... Is this 1980?”

    • Read More

    News

    NCI mammography trial mostly a ‘waste,’ says expert 

    Author:
    Nick Mulcahy
    Publish date: November 8, 2021

    Harvard physician says TMIST is underpowered and as a result, may be misleading.

    • Read More

    News

    Does eating nuts lead to better breast cancer outcomes?

    Author:
    Nick Mulcahy
    Publish date: October 20, 2021

    A little may go a long way, as research to date “suggests only small amounts may be needed to gain potential benefits.”

    • Read More

    News

    FDA approves first CAR T-cell for adult ALL: For patients with R/R B-cell disease

    Author:
    Nick Mulcahy
    Publish date: October 6, 2021

    “This is a meaningful advance because roughly half of all adults with B-ALL will relapse on currently available therapies.”

    • Read More

    News

    ‘Beloved’ fired oncologist inspires patient-funded billboards

    Author:
    Nick Mulcahy
    Publish date: September 29, 2021

    “This is something of a phenomenon — this doctor is so beloved in this community. We will not give up.”

    • Read More

    News

    Call for a move or boycott of big Texas cancer meeting

    Author:
    Nick Mulcahy
    Publish date: September 21, 2021

    “I think that if Texas officials understood that when they pass laws inhospitable to women, we will not hold a major conference about women’s...

    • Read More

    News

    Patients panic as docs cut off breast cancer drug

    Author:
    Nick Mulcahy
    Publish date: September 20, 2021

    Experts say discontinuing atezolizumab is not advised if a patient is responding or is stable.

    • Read More

    News

    Flurry of cancer drug endorsements from EU panel

    Author:
    Nick Mulcahy
    Publish date: September 20, 2021

    Approvals include pralsetinib for non-small cell lung cancer, ripretinib for advanced gastrointestinal stromal tumor, and zanubrutinib for...

    • Read More

    News

    FDA approves first oral drug for NSCLC with EGFR Exon 20 insertion

    Author:
    Nick Mulcahy
    Publish date: September 20, 2021

    Mobocertinib is the first oral tyrosine kinase inhibitor for patients with metastatic non–small cell lung cancer who have an EGFR Exon 20...

    • Read More

    Pages

    • 1
    • 2
    • 3
    • 4
    • 5
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery